In this study, breast cancer clinical samples treated prospectively, together with in vitro functional studies, concordantly show simvastatin to induce apoptosis, inhibit proliferation and suppress PI3K/Akt/mTOR and MAPK/ERK pathways in breast cancer, and these anti-tumoral effects are achieved by inhibiting the mevalonate pathway. Here, MTOR is linked to breast carcinoma.